Rosacea is a common condition affecting the skin of the face, with less frequent involvement of the eyes. Nonspecific ocular complications are similar to those found in patients with seborrhoea, blepharitis, recurrent chalazia, styes and trichiasis, hyperaemic conjunctivitis, with occasional marginal corneal infiltrates or ulcers. Specific complications include nodular conjunctivitis and episcleritis, which are rare, and the typical progressive keratitis which occurs in 5% of patients with rosacea.I Oxytetracycline given orally in low dosage for more than 6 weeks is a well recognised treatment for rosacea of the skin2' and is also reassuringly safe.7 Tetracycline has been used topically in ocular rosacea,8 and there is increasing evidence that rosacea keratitis may also respond to systemic tetracyclines.
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I "" I The purpose of this study was to assess the validity of these observations by means of a double-blind limited cross-over trial.
Material and methods
Patients attending dermatology clinics with confirmed rosacea were questioned for possible eye symptoms. Sixty-five were subsequently screened by an ophthalmologist and were admitted to the trial if their symptom and sign score (see below) reached a minimum level and if there were no general contraindications to the use of tetracyclines-pregnancy and lactation, hepatic or renal disease, drug allergy, or chronic bronchitis. Thirty-five patients were admitted to the trial.
Symptoms and signs were scored as absent (0), moderate (1), or severe (2). Symptoms were listed as: irritation, discharge, swelling of lids, redness, photophobia, pain, loss of sight. Signs were listed as: redness, swelling, discharge and chalazia for the eyelids, and redness, nodules, dilatation of vessels, tortuosity of vessels and microaneurysms for the conjunctiva and new vessels, superficial punctate keratitis, infiltrates, ulcers, and healed scars for the cornea. Left and right eyes were assessed separately. The maximum score for either eye was therefore 14 points for symptoms and 28 points for signs. A minimum of 25% score for symptoms and signs was required for admission to the trial.
On admission to the trial treatment was started with 250 mg unmarked identical capsules containing either oxytetracycline dihydrate (Clinimycin) or a placebo of identical appearance composed of dextrose. Either capsule was taken in a dose of one capsule twice daily on an empty stomach. No local eye treatment was given.
The trial was divided into treatment periods. These were defined as a 6-week period on the drug or placebo followed by a 6-week observation period on 386 no drug (to allow for possible carry-over effects). Patients were kept on the trial for a minimum of 3 treatment periods. They were examined every 6 weeks.
Those who responded to the first course of treatment were left untreated but received the same agent if a relapse occurred. Those The remissions over the first treatment period are shown in Table 2 . There was a significantly higher rate of remission (partial and full) for patients taking oxytetracycline (p<005).
Complications/side effects of the treatment. Two patients withdrew from the trial. One complained of nausea and sickness and refused to take any more tablets; the tablets were subsequently found to be the placebo. The other patient developed a corneal ulcer and had to be given specific topical treatment. There was a delay in response to oxytetracycline of about 2 weeks in most patients. Relapses generally occurred 2-3 weeks after stopping oxytetracycline but were occasionally immediate.
Discussion
It is difficult in ocular rosacea, where spontaneous exacerbations and remissions occur, to be sure whether clinical improvement is related to specific drug treatment or is merely part of the natural 
